The ECHELON-2 trial: Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A plus CHP) vs CHOP in the frontline treatment of patients (pts) with CD30+ peripheral T-cell lymphomas (PTCLs)

被引：0

作者：

Truemper, L. ^{[1
]}

O'Connor, O. A. ^{[2
]}

Pro, B. ^{[3
]}

Illidge, T. M. ^{[4
]}

Advani, R. H. ^{[5
]}

Bartlett, N. L. ^{[6
]}

Christensen, Haaber J. ^{[7
]}

Morschhauser, F. ^{[8
]}

Domingo-Domenech, E. ^{[9
]}

Rossi, G. ^{[10
]}

Kim, W. S. ^{[11
]}

Feldman, T. A. ^{[12
]}

Lennard, A. ^{[13
]}

Belada, D. ^{[14
,15
]}

Illes, A. ^{[16
]}

Tobinai, K. ^{[17
]}

Tsukasaki, K. ^{[18
]}

Yeh, S. -P. ^{[19
]}

Shustov, A. R. ^{[20
]}

Huettmann, A. ^{[21
]}

Savage, K. J. ^{[22
,23
]}

Yuen, S. ^{[24
]}

Iyer, S. ^{[25
]}

Zinzani, P. L. ^{[26
]}

Hua, Z. ^{[27
]}

Little, M. ^{[27
]}

Rao, S. ^{[28
]}

Woolery, J. ^{[28
]}

Manley, T. ^{[28
]}

Horwitz, S. M. ^{[29
]}

机构：

[1] Univ Med Gottingen, Dept Hematol & Oncol, Gottingen, Germany

[2] Columbia Univ, Med Ctr, Div Hematol Oncol, New York, NY USA

[3] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA

[4] Univ Manchester, Div Canc Sci, Fac Biol Med & Hlth,Christie Hosp NHS Fdn Trust, NIHR Biomed Res Ctr,Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England

[5] Stanford Canc Ctr, Blood & Marrow Transplant Program, Palo Alto, CA USA

[6] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[7] Odense Univ Hosp, Dept Hematol, Odense, Denmark

[8] CHRU Lille, Dept Hematol, Lille, France

[9] Inst Catala Oncol, Dept Hematol, Barcelona, Spain

[10] Azienda Osped Spedali Civili Brescia, Dept Hematol, Brescia, Italy

[11] Samsung Med Ctr, Seoul, South Korea

[12] Hackensack Univ Med Ctr, Hackensack, NJ USA

[13] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England

[14] Univ Hosp, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[15] Charles Univ Prague, Fac Med, Prague, Czech Republic

[16] Debreceni Egyet, Debrecen, Hungary

[17] Natl Canc Ctr, Dept Hematol, Tokyo, Japan

[18] Saitama Med Univ, Int Med Ctr, Dept Hematol, Saitama, Japan

[19] China Med Univ Hosp, Taichung, Taiwan

[20] Univ Washington, Med Ctr, Div Hematol, Seattle, WA 98195 USA

[21] Univ Klinikum Essen, Klin Hamatol, Essen, Germany

[22] Univ British Columbia, Dept Med Oncol, Vancouver, BC, Canada

[23] British Columbia Canc Agcy, Dept Med Oncol, Ctr Lymphoid Canc, Vancouver, BC, Canada

[24] Calvary Mater Newcastle Hosp, Dept Hematol, Waratah, Australia

[25] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[26] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[27] Takeda Pharmaceut Int Co, Cambridge, MA USA

[28] Seattle Genet Inc, Bothell, WA USA

[29] Mem Sloan Kettering Canc Ctr, Dept Med, Basking Ridge, NJ USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V99

引用

页码：23 / 23

页数：1

共 32 条

[21] Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study
Fanale, Michelle A.
Horwitz, Steven M.
Forero-Torres, Andres
Bartlett, Nancy L.
Advani, Ranjana H.
Pro, Barbara
Chen, Robert W.
Davies, Andrew
Illidge, Tim
Huebner, Dirk
Kennedy, Dana A.
Shustov, Andrei R.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) : 3137 - +
[22] Frontline Treatment of CD30+Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up
Horwitz, Steven M.
Shustov, Andrei R.
Forero-Torres, Andres
Bartlett, Nancy L.
Advani, Ranjana
Pro, Barbara
Chen, Robert
Davies, Andrew J.
Illidge, Tim
Huebner, Dirk
Kennedy, Dana A.
Fanale, Michelle A.
BLOOD, 2015, 126 (23)
[23] The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
Horwitz, S.
O'Connor, O. A.
Pro, B.
Trumper, L.
Iyer, S.
Advani, R.
Bartlett, N. L.
Christensen, J. H.
Morschhauser, F.
Domingo-Domenech, E.
Rossi, G.
Kim, W. S.
Feldman, T.
Menne, T.
Belada, D.
Illes, A.
Tobinai, K.
Tsukasaki, K.
Yeh, S-P
Shustov, A.
Huettmann, A.
Savage, K. J.
Yuen, S.
Zinzani, P. L.
Miao, H.
Bunn, V
Fenton, K.
Fanale, M.
Puhlmann, M.
Illidge, T.
ANNALS OF ONCOLOGY, 2022, 33 (03) : 288 - 298
[24] BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHP IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED CD30+PERIPHERAL T-CELL LYMPHOMAS (PTCL): 2-YEAR FOLLOW-UP
Fanale, M. A.
Horwitz, S. M.
Forero-Torres, A.
Bartlett, N. L.
Advani, R. H.
Pro, B.
Chen, R. W.
Davies, A.
Illidge, T.
Huebner, D.
Kennedy, D. A.
Shustov, A. R.
ANNALS OF ONCOLOGY, 2014, 25
[25] ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results
Illidge, Timothy
Horwitz, Steven M.
O'Connor, Owen A.
Pro, Barbara
Iyer, Swami P.
Advani, Ranjana
Bartlett, Nancy L.
Christensen, Jacob Haaber
Morschhauser, Franck
Domingo-Domenech, Eva
Rossi, Giuseppe
Kim, Won Seog
Feldman, Tatyana A.
Menne, Tobias
Belada, David
Illes, Arpad
Tobinai, Kensei
Tsukasaki, Kunihiro
Yeh, Su-Peng
Huettmann, Andreas
Savage, Kerry J.
Yuen, Sam
Zinzani, Pier Luigi
Miao, Harry
Bunn, Veronica
Fenton, Keenan
Fanale, Michelle A.
Puhlmann, Markus
Truemper, Lorenz
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 38 - 40
[26] Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial
Svoboda, Jakub
Landsburg, Daniel J.
Nasta, Sunita Dwivedy
Barta, Stefan Klaus
Khan, Nadia
Fung, Henry C.
Tan, Carlyn Rose
Filicko-O'Hara, Joanne
Gaballa, Sameh
Strelec, Lauren Elizabeth
Nagle, Sarah J.
Bair, Steven M.
Mitnick, Sheryl
Waite, Terease S.
Sargent, Rachel Lynn
Bogusz, Agata M.
Sahin, Ziver
Mato, Anthony R.
Schuster, Stephen J.
BLOOD, 2017, 130
[27] Brentuximab Vedotin With R-CHP Chemotherapy as Frontline Treatment for Patients With CD30-Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial
Moskowitz, Craig H.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 9 - 10
[28] Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas
Herrera, Alex F.
Zain, Jasmine
Savage, Kerry J.
Feldman, Tatyana A.
Brammer, Jonathan E.
Chen, Lu
Popplewell, Leslie L.
Budde, Lihua E.
Peters, Lacolle
Kurtzman, Yaira
Forman, Stephen J.
Rosen, Steven
Kwak, Larry W.
Iyer, Swaminathan P.
BLOOD, 2019, 134
[29] The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma
Sibon, David
Khater, Sherine
Bruneau, Julie
Brouzes, Chantal
Lhermitte, Ludovic
Molina, Thierry Jo
Cartron, Guillaume
Morel, Veronique
Malamut, Georgia
Chauchet, Adrien
Morschhauser, Franck
Perard, Baptiste
Boulet, Jean-Michel
Gauchy, Anne-Cecile
Cerf-Bensussan, Nadine
Macintyre, Elizabeth A.
Asnafi, Vahid
Cellier, Christophe
Hermine, Olivier
BLOOD, 2021, 138
[30] The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (02) : 4 - 6

← 1 2 3 4 →